[
  {
    "ts": null,
    "headline": "Trillion-Dollar Companies Now Go To 11; Google Is No. 3",
    "summary": "Eli Lilly recently became the 11th stock with a trillion-dollar valuation. S&P 500 titans Nvidia and Apple lead, but Google is rising fast.",
    "url": "https://finnhub.io/api/news?id=b36c1e0f27f4163bc419f6d66891d0d303cd47813c3b08313defd3789ab74d0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764627643,
      "headline": "Trillion-Dollar Companies Now Go To 11; Google Is No. 3",
      "id": 137658655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly recently became the 11th stock with a trillion-dollar valuation. S&P 500 titans Nvidia and Apple lead, but Google is rising fast.",
      "url": "https://finnhub.io/api/news?id=b36c1e0f27f4163bc419f6d66891d0d303cd47813c3b08313defd3789ab74d0a"
    }
  },
  {
    "ts": null,
    "headline": "Stocks To Watch As Google Drives Rattled But Rebounding Market",
    "summary": "As the Nasdaq holds tough after a five-day win streak, Google stock, Robinhood and others land on list of stocks to watch.",
    "url": "https://finnhub.io/api/news?id=f2d68e5a8eb6a61d00e781ba9293c4b3eb246efd7829ebb65fc0fb8112e954b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764627126,
      "headline": "Stocks To Watch As Google Drives Rattled But Rebounding Market",
      "id": 137658759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the Nasdaq holds tough after a five-day win streak, Google stock, Robinhood and others land on list of stocks to watch.",
      "url": "https://finnhub.io/api/news?id=f2d68e5a8eb6a61d00e781ba9293c4b3eb246efd7829ebb65fc0fb8112e954b4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal",
    "summary": "Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, about a month after striking a deal with the Trump administration to lower drug costs.",
    "url": "https://finnhub.io/api/news?id=a91463d1f72dfa1d3f49f9d4d9f3442d70f3d047d479092cbf308896426d231b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764623434,
      "headline": "Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal",
      "id": 137658833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, about a month after striking a deal with the Trump administration to lower drug costs.",
      "url": "https://finnhub.io/api/news?id=a91463d1f72dfa1d3f49f9d4d9f3442d70f3d047d479092cbf308896426d231b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect",
    "summary": "The company lowered monthly out-of-pocket costs as access initiatives expand.",
    "url": "https://finnhub.io/api/news?id=c4592fd155918b39fed9f0b723e61113627ca55f51e80ca148feffb317bb8ce9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764619751,
      "headline": "Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect",
      "id": 137658834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company lowered monthly out-of-pocket costs as access initiatives expand.",
      "url": "https://finnhub.io/api/news?id=c4592fd155918b39fed9f0b723e61113627ca55f51e80ca148feffb317bb8ce9"
    }
  },
  {
    "ts": null,
    "headline": "U.S., U.K. Strike Deal on Higher Drug Prices",
    "summary": "The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.",
    "url": "https://finnhub.io/api/news?id=4bc02f2343ae67bb9b8f526f5a9d3f3169ed6ce73bf0ac56cf488bd54df180d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764613980,
      "headline": "U.S., U.K. Strike Deal on Higher Drug Prices",
      "id": 137658835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.",
      "url": "https://finnhub.io/api/news?id=4bc02f2343ae67bb9b8f526f5a9d3f3169ed6ce73bf0ac56cf488bd54df180d9"
    }
  },
  {
    "ts": null,
    "headline": "Are GLP-1s The New Performance-Enhancing Drug For Careers?",
    "summary": "Some professions — think tenured professor or Supreme Court justice — are largely insulated from the pressure to maintain a specific look. The same cannot be said in the high-stakes arenas of finance, real estate and design, where the quest for a competitive edge has well-established self-maintenance rituals: coloring gray hairs, meticulously curated wardrobe and submitting oneself to Botox needles. Now, that pursuit has evolved to include another new, potent class of injectable: glucagon-like p",
    "url": "https://finnhub.io/api/news?id=7e224b4b5d23bf7f7ef390d0a88cb4af93e519fda8d841c0f5cd184945292ce0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764608469,
      "headline": "Are GLP-1s The New Performance-Enhancing Drug For Careers?",
      "id": 137658836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Some professions — think tenured professor or Supreme Court justice — are largely insulated from the pressure to maintain a specific look. The same cannot be said in the high-stakes arenas of finance, real estate and design, where the quest for a competitive edge has well-established self-maintenance rituals: coloring gray hairs, meticulously curated wardrobe and submitting oneself to Botox needles. Now, that pursuit has evolved to include another new, potent class of injectable: glucagon-like p",
      "url": "https://finnhub.io/api/news?id=7e224b4b5d23bf7f7ef390d0a88cb4af93e519fda8d841c0f5cd184945292ce0"
    }
  },
  {
    "ts": null,
    "headline": "AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.",
    "url": "https://finnhub.io/api/news?id=78d2fbdffc373e7d6e89b8f8320cc8da650da2e6559f9b9f047819ae4b04b2ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764604800,
      "headline": "AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?",
      "id": 137658837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.",
      "url": "https://finnhub.io/api/news?id=78d2fbdffc373e7d6e89b8f8320cc8da650da2e6559f9b9f047819ae4b04b2ca"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly cuts cash prices on single dose vials of weight-loss drug Zepbound",
    "summary": "CNBC's Annika Kim Constantino reports on news regarding Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=28212351b646b06ef20731a1c706b10095d5fa3cb3d7d37d080e9cf77cfcec1d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764604404,
      "headline": "Eli Lilly cuts cash prices on single dose vials of weight-loss drug Zepbound",
      "id": 137663833,
      "image": "https://image.cnbcfm.com/api/v1/image/108234734-17646222391764622237-42774614732-1080pnbcnews.jpg?v=1764622238&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "CNBC's Annika Kim Constantino reports on news regarding Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=28212351b646b06ef20731a1c706b10095d5fa3cb3d7d37d080e9cf77cfcec1d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound",
    "summary": "Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50. It's part of the price war with rival Novo Nordisk. Bloomberg's Madison Muller reports.",
    "url": "https://finnhub.io/api/news?id=a1c348cdc436287594ed46a1c6f5f422e816bb00fffc967fd53ba328c2250c8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764602043,
      "headline": "Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound",
      "id": 137658838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50. It's part of the price war with rival Novo Nordisk. Bloomberg's Madison Muller reports.",
      "url": "https://finnhub.io/api/news?id=a1c348cdc436287594ed46a1c6f5f422e816bb00fffc967fd53ba328c2250c8f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly cuts cash price for Zepbound weight loss drug vials",
    "summary": "The announcement came just weeks after rival Novo Nordisk cut prices for cash buyers of its top-selling weight loss drugs Ozempic and Wegovy",
    "url": "https://finnhub.io/api/news?id=94969482b4b049e7ee80644c957180ea5f393960db05bd43bab7017fc714258d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764601456,
      "headline": "Eli Lilly cuts cash price for Zepbound weight loss drug vials",
      "id": 137658839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The announcement came just weeks after rival Novo Nordisk cut prices for cash buyers of its top-selling weight loss drugs Ozempic and Wegovy",
      "url": "https://finnhub.io/api/news?id=94969482b4b049e7ee80644c957180ea5f393960db05bd43bab7017fc714258d"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Stock Rises 34% in Three Months: Here's What You Should Know",
    "summary": "Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.",
    "url": "https://finnhub.io/api/news?id=1d5a6130ab74aedcf6be0416607e5824cfb54393a2b573332ca3d0a8b023dd95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764599160,
      "headline": "VKTX Stock Rises 34% in Three Months: Here's What You Should Know",
      "id": 137658840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.",
      "url": "https://finnhub.io/api/news?id=1d5a6130ab74aedcf6be0416607e5824cfb54393a2b573332ca3d0a8b023dd95"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly cuts price for popular weight loss drug Zepbound",
    "summary": "Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's LillyDirect website.",
    "url": "https://finnhub.io/api/news?id=6df58a89914534ef2f6fa8429fd2df57b8b460c9c317fcb9a6db14d29fbfb573",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764595652,
      "headline": "Eli Lilly cuts price for popular weight loss drug Zepbound",
      "id": 137658841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's LillyDirect website.",
      "url": "https://finnhub.io/api/news?id=6df58a89914534ef2f6fa8429fd2df57b8b460c9c317fcb9a6db14d29fbfb573"
    }
  },
  {
    "ts": null,
    "headline": "DraftKings Stock Has Gotten Whacked. Why JPMorgan Says It Can Mount a Comeback.",
    "summary": "Kalshi and Polymarket may not be a threat for much longer, as the gambling company gears up to launch its own prediction market.",
    "url": "https://finnhub.io/api/news?id=9138b451da7ad9887a77d1b4f04bc58f52a27fed18504f9a8a896bd9a7ebf99c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764595140,
      "headline": "DraftKings Stock Has Gotten Whacked. Why JPMorgan Says It Can Mount a Comeback.",
      "id": 137658842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Kalshi and Polymarket may not be a threat for much longer, as the gambling company gears up to launch its own prediction market.",
      "url": "https://finnhub.io/api/news?id=9138b451da7ad9887a77d1b4f04bc58f52a27fed18504f9a8a896bd9a7ebf99c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.",
    "summary": "A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?",
    "url": "https://finnhub.io/api/news?id=19803d5c609c2fc3b36d80b60dce84833ec14b98ac2e4456a9bc9d1ff7e35cae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764590820,
      "headline": "Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.",
      "id": 137658843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?",
      "url": "https://finnhub.io/api/news?id=19803d5c609c2fc3b36d80b60dce84833ec14b98ac2e4456a9bc9d1ff7e35cae"
    }
  },
  {
    "ts": null,
    "headline": "Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly",
    "summary": "Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a LiquidationREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by E",
    "url": "https://finnhub.io/api/news?id=c81314ed7d52395d56dab694d76cb10cc7048deac1422f934efec3e249b2561c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764590400,
      "headline": "Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly",
      "id": 137658844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a LiquidationREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by E",
      "url": "https://finnhub.io/api/news?id=c81314ed7d52395d56dab694d76cb10cc7048deac1422f934efec3e249b2561c"
    }
  },
  {
    "ts": null,
    "headline": "US Stock Market Today: S&P 500 Futures Dip as Rate Cut Uncertainty Weighs",
    "summary": "The Morning Bull - US Market Morning Update Monday, Dec, 1 2025 US stock futures are drifting lower this morning as investors digest two big drivers: rising expectations of a Federal Reserve interest rate cut and a fresh jump in Treasury yields. The yield on the 10-year US government bond climbed to 4.04%, which signals that borrowing money is still expensive for both consumers and businesses. At the same time, market chatter points to a likely rate cut as soon as next week, which could make...",
    "url": "https://finnhub.io/api/news?id=1a99be9141480b34ebcac75138b858dc51508022c1cd83f8f49128afb0971606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764583713,
      "headline": "US Stock Market Today: S&P 500 Futures Dip as Rate Cut Uncertainty Weighs",
      "id": 137658845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Morning Bull - US Market Morning Update Monday, Dec, 1 2025 US stock futures are drifting lower this morning as investors digest two big drivers: rising expectations of a Federal Reserve interest rate cut and a fresh jump in Treasury yields. The yield on the 10-year US government bond climbed to 4.04%, which signals that borrowing money is still expensive for both consumers and businesses. At the same time, market chatter points to a likely rate cut as soon as next week, which could make...",
      "url": "https://finnhub.io/api/news?id=1a99be9141480b34ebcac75138b858dc51508022c1cd83f8f49128afb0971606"
    }
  },
  {
    "ts": null,
    "headline": "The weight loss drug boom is just getting started: What's next",
    "summary": "New pill versions of weight loss drugs, lower prices, and patent expirations will all drive GLP-1 demand in 2026",
    "url": "https://finnhub.io/api/news?id=4951862702af0d3beec154861b45b5a84e6e8af2760af7e7aebd5a22ded1b253",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764583200,
      "headline": "The weight loss drug boom is just getting started: What's next",
      "id": 137658846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New pill versions of weight loss drugs, lower prices, and patent expirations will all drive GLP-1 demand in 2026",
      "url": "https://finnhub.io/api/news?id=4951862702af0d3beec154861b45b5a84e6e8af2760af7e7aebd5a22ded1b253"
    }
  },
  {
    "ts": null,
    "headline": "How Analyst Views Are Shaping Eli Lilly’s Evolving Growth Story",
    "summary": "Eli Lilly’s stock has recently seen its consensus analyst price target rise from $1,003 to $1,024. This change reflects growing optimism among investors and follows fresh analyst reports and updated financial models, which are influenced by new product launches and expanding drug coverage. Stay tuned to discover how you can track these evolving perspectives and remain informed about future changes in Eli Lilly’s investment narrative. Stay updated as the Fair Value for Eli Lilly shifts by...",
    "url": "https://finnhub.io/api/news?id=3b00804926cb065870d447075a1a1011cbc0d96feff7c5c21d6e4ef2f8e5c57c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764580215,
      "headline": "How Analyst Views Are Shaping Eli Lilly’s Evolving Growth Story",
      "id": 137650521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s stock has recently seen its consensus analyst price target rise from $1,003 to $1,024. This change reflects growing optimism among investors and follows fresh analyst reports and updated financial models, which are influenced by new product launches and expanding drug coverage. Stay tuned to discover how you can track these evolving perspectives and remain informed about future changes in Eli Lilly’s investment narrative. Stay updated as the Fair Value for Eli Lilly shifts by...",
      "url": "https://finnhub.io/api/news?id=3b00804926cb065870d447075a1a1011cbc0d96feff7c5c21d6e4ef2f8e5c57c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=b46220b3ceed0703f477ed2c65875140232bebba7a05d4570ff36f3c8e644389",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764576329,
      "headline": "Eli Lilly's price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk",
      "id": 137654012,
      "image": "https://image.cnbcfm.com/api/v1/image/108015610-1722607003040-gettyimages-2158420275-BC_24SChart4500.jpeg?v=1764542465&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=b46220b3ceed0703f477ed2c65875140232bebba7a05d4570ff36f3c8e644389"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site",
    "summary": "The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.",
    "url": "https://finnhub.io/api/news?id=2bacddd8aa3689b8bd9eb07b9d493d724f8e83e92681a0cd88113734f7dcf1f2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764576001,
      "headline": "Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site",
      "id": 137654014,
      "image": "https://image.cnbcfm.com/api/v1/image/108230176-1764603822722-108230176-17637559702025-11-21t201158z_1546648356_rc261iafo6zz_rtrmadp_0_lilly-stocks.jpg?v=1764603832&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access. ",
      "url": "https://finnhub.io/api/news?id=2bacddd8aa3689b8bd9eb07b9d493d724f8e83e92681a0cd88113734f7dcf1f2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The GLP-1 Leader's Sky-High P/E Makes It A Clear Hold",
    "summary": "Discover if Eli Lilly's (LLY) record growth in GLP-1 and diabetes drugs justifies its valuation. See if now is the right time to buy or hold.",
    "url": "https://finnhub.io/api/news?id=8a47631e148317e9507bf255d1ddd87ed2338c466cb4535fe995785cd43a0e21",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764564898,
      "headline": "Eli Lilly: The GLP-1 Leader's Sky-High P/E Makes It A Clear Hold",
      "id": 137651428,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1793099940/image_1793099940.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover if Eli Lilly's (LLY) record growth in GLP-1 and diabetes drugs justifies its valuation. See if now is the right time to buy or hold.",
      "url": "https://finnhub.io/api/news?id=8a47631e148317e9507bf255d1ddd87ed2338c466cb4535fe995785cd43a0e21"
    }
  }
]